Maravai LifeSciences
MRVI
7.43
-0.42
-5.35%
Maravai LifeSciences
US · MRVI
#3116 by market cap
Listed 2020
7.43
-0.42
-5.35%
Live - 5344 symbols - heartbeat 94s ago
· 2026-10-08 07:41
Pre-market
7.64
+2.83%
After-hours
7.44
+0.13%
- Market cap
- 1.11B
- P/E (TTM)i
- -14.02
- P/Bi
- 5.41
- EPSi
- -0.90
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on MRVI?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.77, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -28.34% YoY
Margins
- Gross margin
- 18.30%
- Operating margin
- -69.20%
- Net margin
- -70.41%
Key ratios & quality
- Enterprise valuei
- 1.19B
- Altman Z-Scorei
- 1.77
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 123.83M | 143.14M | 284.10M | 799.24M | 883.00M | 288.95M | 259.19M | 185.74M |
| Gross profit | 63.07M | 76.29M | 204.45M | 658.68M | 714.04M | 140.20M | 108.31M | 33.99M |
| Selling & admin expenses | 41.19M | 48.35M | 94.25M | 100.06M | 129.26M | 151.39M | 161.77M | 145.12M |
| Research & development | 4.50M | 3.63M | 9.30M | 15.22M | 18.37M | 17.28M | 19.22M | 17.40M |
| Operating profit | 17.38M | 24.31M | 100.90M | 543.40M | 566.42M | -28.47M | -72.68M | -128.53M |
| Pretax profit | -16.50M | -5.85M | 81.70M | 530.77M | 551.47M | 617.74M | -261.48M | -234.97M |
| Tax | 417.00K | -652.00K | 2.88M | 61.52M | 60.81M | 756.11M | -1.86M | -4.21M |
| Net profit | -16.92M | -5.20M | 78.82M | 469.25M | 490.66M | -138.38M | -259.62M | -230.76M |
| Basic EPS | 0 | 0 | 7 | 2 | 2 | -1 | -1 | -1 |
| Diluted EPS | -0.20 | -0.10 | 2.36 | 1.56 | 1.67 | -0.90 | -1.05 | -0.90 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 46.85M | 47.40M | 41.63M | 49.87M | 65.84M | 51.44M |
| Gross profit | 7.73M | 7.77M | 5.66M | 12.84M | 33.70M | 20.65M |
| Selling & admin expenses | 39.56M | 38.72M | 35.40M | 31.58M | 29.09M | 32.07M |
| Research & development | 4.89M | 4.88M | 3.84M | 3.79M | 3.89M | 3.70M |
| Operating profit | -36.73M | -35.83M | -33.59M | -22.53M | 720.00K | -15.12M |
| Pretax profit | -52.69M | -74.13M | -45.15M | -63.01M | -6.53M | -21.80M |
| Tax | 162.00K | -4.29M | -92.00K | 6.00K | -151.00K | -171.00K |
| Net profit | -52.85M | -69.84M | -45.06M | -63.02M | -6.38M | -21.63M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.21 | -0.27 | -0.18 | -0.24 | -0.02 | -0.08 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 53.80M | 60.55M | 331.60M | 740.04M | 847.90M | 699.91M | 429.15M | 296.25M |
| Cash & ST investments | 21.87M | 24.70M | 236.18M | 551.27M | 632.14M | 574.96M | 322.40M | 216.89M |
| Inventory | 14.31M | 14.20M | 33.30M | 51.56M | 43.15M | 51.40M | 50.08M | 40.50M |
| Total assets | 539.68M | 577.80M | 1.27B | 1.92B | 2.28B | 1.49B | 1.01B | 770.58M |
| Total current liabilities | 35.92M | 29.56M | 130.78M | 93.78M | 110.14M | 87.47M | 56.97M | 44.92M |
| Short-term debt | 2.50M | 2.50M | 6.00M | 9.72M | 11.71M | 12.85M | 13.71M | 14.20M |
| Long-term debt | 335.55M | 334.78M | 528.61M | 524.59M | 522.00M | 518.71M | 290.49M | 286.33M |
| Total liabilities | 391,660,000.00 | 433,169,000.00 | 1,115,945,000.00 | 1,372,915,000.00 | 1,377,072,000.00 | 697,566,000.00 | 431,035,000.00 | 397,866,000.00 |
| Total equity | 148.02M | 144.63M | 154.75M | 545.36M | 905.24M | 789.88M | 577.21M | 372.71M |
| Retained earnings | -38.24M | -42.38M | 854.00K | 184.56M | 404.77M | 285.74M | 140.89M | 10.12M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 376.28M | 359.76M | 325.87M | 296.25M | 251.74M | 155.66M |
| Cash & ST investments | 285.05M | 269.91M | 243.57M | 216.89M | 165.92M | 70.09M |
| Inventory | 49.77M | 46.67M | 45.33M | 40.50M | 40.46M | 41.23M |
| Total assets | 959.75M | 896.97M | 849.19M | 770.58M | 713.22M | 603.75M |
| Total current liabilities | 63.16M | 69.68M | 61.57M | 44.92M | 42.62M | 38.42M |
| Short-term debt | 6.27M | 6.32M | 14.50M | 14.20M | 5.44M | 1.13M |
| Long-term debt | 289.50M | 288.44M | 287.38M | 286.33M | 235.57M | 145.98M |
| Total liabilities | 429,478,000.00 | 428,983,000.00 | 417,332,000.00 | 397,866,000.00 | 344,134,000.00 | 248,158,000.00 |
| Total equity | 530.27M | 467.98M | 431.86M | 372.71M | 369.08M | 355.59M |
| Retained earnings | 110.95M | 71.36M | 45.80M | 10.12M | 6.39M | -6.03M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -186.00K | 24.12M | 152.19M | 368.57M | 535.98M | 126.22M | 7.47M | -57.57M |
| Depreciation & amortization | 22.35M | 24.08M | 25.84M | 33.54M | 38.10M | 48.78M | 56.87M | 60.47M |
| Free cash flow | -3.80M | 6.97M | 126.78M | 353.72M | 518.89M | 60.67M | -22.19M | -70.72M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 300.95M | -- | -- | -- | -- | -- |
| Ending cash balance | 21.87M | 24.70M | 236.18M | 551.27M | 632.14M | 574.96M | 322.40M | 216.89M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -9.39M | -10.27M | -15.15M | -22.77M | 8.67M | 3.99M |
| Depreciation & amortization | 14.91M | 15.39M | 15.44M | 14.73M | 12.98M | 13.41M |
| Free cash flow | -13.89M | -13.14M | -18.81M | -24.88M | 4.23M | 3.62M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 285.05M | 269.91M | 243.57M | 216.89M | 165.92M | 70.58M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -12.28 | -3.13 | 66.89 | 90.12 | 51.17 | -24.75 | -39.04 | -48.64 |
| ROA %i | -3.29 | -0.80 | 8.32 | 11.42 | 10.48 | -6.31 | -11.61 | -14.70 |
| ROIC %i | 0.47 | 4.36 | 17.60 | 27.31 | 23.86 | -9.70 | -14.42 | -18.06 |
| 5-year avg ROE %i | -- | -- | -- | -- | 37.99 | 35.50 | 28.88 | 5.77 |
| EBIT margin %i | 8.80 | 16.84 | 39.58 | 70.19 | 64.77 | 229.67 | -82.48 | -111.97 |
| FCF / sales %i | -- | 4.87 | 44.63 | 44.26 | 58.76 | 21.00 | -- | -- |
| Current ratioi | 1.50 | 2.05 | 2.54 | 7.89 | 7.70 | 8.00 | 7.53 | 6.60 |
| Quick ratioi | 1.05 | 1.45 | 2.20 | 7.13 | 7.07 | 7.20 | 6.34 | 5.40 |
| Debt / assetsi | 62.98 | 67.53 | 46.49 | 29.99 | 25.64 | 41.07 | 37.36 | 47.33 |
| LT debt / equityi | 233.64 | 274.20 | 660.69 | 179.24 | 105.20 | 143.52 | 111.59 | 165.04 |
| Interest coveragei | 0.40 | 0.80 | 3.66 | 18.54 | 28.01 | 14.46 | -4.48 | -7.71 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 86.19 | 83.40 | 0.57 | -31.30 | -40.53 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | 320.74 | -21.78 | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -45.75 | -54.79 | -40.98 | -48.64 | -40.83 | -32.90 |
| ROA %i | -13.53 | -16.42 | -11.38 | -14.70 | -12.50 | -10.31 |
| ROIC %i | -17.35 | -21.32 | -13.78 | -18.06 | -15.44 | -12.21 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -102.60 | -139.45 | -96.83 | -111.97 | -79.54 | -53.90 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.96 | 5.16 | 5.29 | 6.60 | 5.91 | 4.05 |
| Quick ratioi | 4.96 | 4.27 | 4.32 | 5.40 | 4.68 | 2.63 |
| Debt / assetsi | 38.62 | 40.54 | 43.33 | 47.33 | 37.98 | 29.27 |
| LT debt / equityi | 121.20 | 134.38 | 144.00 | 165.04 | 125.47 | 85.80 |
| Interest coveragei | -5.69 | -7.96 | -5.88 | -7.71 | -6.27 | -4.70 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- TriLink is the largest reported line at 67.39% of revenue, across 2 reported segments.
- Cygnus follows at 32.61%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
TriLink67.39%
Cygnus32.61%
Quote time 2026-10-08 07:41:32 · For reference only, not investment advice and not tailored to your situation.